Log in

Relevant bibliographies by topics / OX40 ligand

Contents

Journal articles
Dissertations / Theses
Book chapters
Conference papers
Reports

Academic literature on the topic 'OX40 ligand'

Author: Grafiati

Published: 4 June 2021

Last updated: 2 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'OX40 ligand.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "OX40 ligand"

1

Blazar, Bruce R., Arlene H. Sharpe, Andy I. Chen, et al. "Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients." Blood 101, no. 9 (2003): 3741–48. http://dx.doi.org/10.1182/blood-2002-10-3048.

Full text

Abstract:

OX40 (CD134) is expressed on activated T cells; its ligand, OX40 ligand (OX40L) is expressed on dendritic cells, B cells, and activated endothelial cells. To determine how OX40-OX40L interaction affects graft-versus-host disease (GVHD), we used antagonistic anti-OX40L monoclonal antibody (mAb) or OX40−/−donor or OX40L−/− recipient mice. Similar degrees of GVHD reduction were observed with each approach. Despite the fact that OX40 is up-regulated on both CD4+ and CD8+ T cells isolated during GVHD, the major effects of OX40 ligation were on CD4+ and not CD8+ T-cell–mediated alloresponses as asse

APA, Harvard, Vancouver, ISO, and other styles

2

Cui, Dawei, Yan Lv, Xinwang Yuan, et al. "Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia." Journal of Immunology Research 2019 (March 3, 2019): 1–8. http://dx.doi.org/10.1155/2019/6804806.

Full text

Abstract:

Background. OX40, which is also known as tumor necrosis factor receptor superfamily member 4 (TNFRSF4), and its ligand (OX40L) play a critical role in the pathogenesis of autoimmune diseases. Immune thrombocytopenia (ITP), a hemorrhagic autoimmune disorder, is characterized by low platelet counts that are predominantly caused by antiplatelet autoantibodies. In this study, we firstly investigated the clinical significance of OX40 and OX40L expression in the pathogenesis of ITP in patients. Methods. Fifty-four newly diagnosed ITP patients and 24 healthy controls (HCs) were enrolled in this study

APA, Harvard, Vancouver, ISO, and other styles

3

Liu, Ye, Beibei Jiang, Tong Zhang, et al. "699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A741. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0699.

Full text

Abstract:

BackgroundOX40 is a member of the tumor necrosis factor receptor super family (TNFRSF) primarily expressed on activated CD4+ and CD8+ T cells, as well as natural killer (NK) T and NK cells. It is an immune costimulatory receptor which binds to its ligand OX40L and activates downstream NF-κB pathway to induce immune cell activation, proliferation, and survival.1–3 Current agonistic anti-OX40 antibodies in clinic, which are mostly ligand-competitive antibodies, showed limited clinical responses, mainly at lower doses. Blockade of OX40-OX40L interaction might limit the efficacy of these ligand-co

APA, Harvard, Vancouver, ISO, and other styles

4

Schumacher, Carla E., Tina Nuebling, Martin Hofmann, et al. "The Role of OX40 and Its Ligand in Acute Myeloid Leukemia: Expression, Function and Modulation of NK Cell Anti-Leukemia Reactivity." Blood 120, no. 21 (2012): 3548. http://dx.doi.org/10.1182/blood.v120.21.3548.3548.

Full text

Abstract:

Abstract Abstract 3548 The TNF/TNF receptor (TNFR) family comprises various molecules that substantially influence cellular functions of both tumor and immune effector cells. The TNFR family member OX40 has been shown to influence proliferation and differentiation of T cells in autoimmune diseases. Here we studied the yet unknown role of OX40 in acute myeloid leukemia (AML). Substantial surface expression of OX40 was detected on malignant cells of AML patients in 24 of 60 (40%) investigated cases. Expression of OX40 mRNA and protein by leukemic cells was confirmed by analysis of AML cells line

APA, Harvard, Vancouver, ISO, and other styles

5

Liu, B., G. Yu, Z. Yang, et al. "Simvastatin Reduces OX40 and OX40 Ligand Expression in Human Peripheral Blood Mononuclear Cells and in Patients with Atherosclerotic Cerebral Infarction." Journal of International Medical Research 37, no. 3 (2009): 601–10. http://dx.doi.org/10.1177/147323000903700302.

Full text

Abstract:

This study investigated the effect of simvastatin on the expression of OX40 and OX40 ligand (OX40L) in vitro and in vivo. OX40 and OX40L mRNA and protein levels were measured in human peripheral blood mononuclear cells, using reverse transcription–polymerase chain reaction and Western blot, respectively, in response to simvastatin alone or given in combination with interferon-γ, mevalonate or GW9662, a peroxisome proliferator-activated receptor-γ (PPAR-γ) antagonist. Simvastatin induced down-regulation of OX40 and OX40L mRNA and protein in a concentration-dependent manner, and antagonized the

APA, Harvard, Vancouver, ISO, and other styles

6

Stüber, E., and W. Strober. "The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response." Journal of Experimental Medicine 183, no. 3 (1996): 979–89. http://dx.doi.org/10.1084/jem.183.3.979.

Full text

Abstract:

Recent in vitro studies have established that activated B cells express OX40 ligand (L), a member of the tumor necrosis factor/nerve growth factor family of cytokines, and become stimulated to proliferate and secrete immunoglobulin (Ig) after cross-linking of OX40L by its counterreceptor OX40, which is expressed on activated T cells. In the present study we investigated the in vivo role of this receptor-ligand pair for the interaction of T and B cells in the course of the T-dependent B cell response against 2,4,6 trinitro-phenyl-keyhole limpet hemocyanin. First, we showed that OX40 is maximall

APA, Harvard, Vancouver, ISO, and other styles

7

Kagami, Yoshitoyo, Dai Chihara, Harumi Kato, Noriaki Yoshida, Tomohiro Kinoshita, and Masao Seto. "FDC Like Cell Line HK With IL-2, IL-4 and OX40 Ligand Supports The Growth Of ATLL Cells." Blood 122, no. 21 (2013): 4319. http://dx.doi.org/10.1182/blood.v122.21.4319.4319.

Full text

Abstract:

Abstract Adult T-cell leukemia/lymphoma (ATLL) is an aggressive neoplasm derived from CD4+ T-cells with HTLV-I infection, and its mechanisms of tumorigenesis still remain to be elucidated. The fact that tumor cells rarely proliferate in vitro is one of the most important problems to be solved. The establishment of cell line from ATLL patient samples has been difficult even in the presence of interleukins. Previously we established one cell line (HU-ATTAK) from acute or lymphoma types of 10 ATLL cases which did not proliferate in the presence of IL-2 and/or IL-4. HU-ATTAK is critically dependen

APA, Harvard, Vancouver, ISO, and other styles

8

Akiba, Hisaya, Yasushi Miyahira, Machiko Atsuta, et al. "Critical Contribution of Ox40 Ligand to T Helper Cell Type 2 Differentiation in Experimental Leishmaniasis." Journal of Experimental Medicine 191, no. 2 (2000): 375–80. http://dx.doi.org/10.1084/jem.191.2.375.

Full text

Abstract:

Infection of inbred mouse strains with Leishmania major is a well characterized model for analysis of T helper (Th)1 and Th2 cell development in vivo. In this study, to address the role of costimulatory molecules CD27, CD30, 4-1BB, and OX40, which belong to the tumor necrosis factor receptor superfamily, in the development of Th1 and Th2 cells in vivo, we administered monoclonal antibody (mAb) against their ligands, CD70, CD30 ligand (L), 4-1BBL, and OX40L, to mice infected with L. major. Whereas anti-CD70, anti-CD30L, and anti–4-1BBL mAb exhibited no effect in either susceptible BALB/c or res

APA, Harvard, Vancouver, ISO, and other styles

9

Flynn, Sarah, Kai-Michael Toellner, Chandra Raykundalia, Margaret Goodall, and Peter Lane. "CD4 T Cell Cytokine Differentiation: The B Cell Activation Molecule, OX40 Ligand, Instructs CD4 T Cells to Express Interleukin 4 and Upregulates Expression of the Chemokine Receptor, Blr-1." Journal of Experimental Medicine 188, no. 2 (1998): 297–304. http://dx.doi.org/10.1084/jem.188.2.297.

Full text

Abstract:

This report investigates the role of OX40 ligand (OX40L) and its receptor, OX40, expressed on activated B and T cells, respectively, in promoting the differentiation of T helper type 2 (Th2) CD4 T cells. These molecules are expressed in vivo by day 2 after priming with T cell– dependent antigens. Their expression coincides with the appearance of immunoglobulin (Ig)G switch transcripts and mRNA for interleukin (IL)-4 and interferon (IFN)-γ, suggesting that this molecular interaction plays a role in early cognate interactions between B and T cells. In vitro, we report that costimulation of naive

APA, Harvard, Vancouver, ISO, and other styles

10

Biagi, Ettore, Gianpietro Dotti, Eric Yvon, et al. "Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor–reactive cytotoxic T lymphocytes." Blood 105, no. 6 (2005): 2436–42. http://dx.doi.org/10.1182/blood-2004-07-2556.

Full text

Abstract:

AbstractClinical benefits from monoclonal antibody therapy for B-chronic lymphocytic leukemia (B-CLL) have increased interest in developing additional immunotherapies for the disease. CD40 ligand is an accessory signal for T-cell activation and can overcome T-cell anergy. The OX40-OX40 ligand pathway is involved in the subsequent expansion of memory antigen-specific T cells. We expressed both CD40L and OX40L on B-CLL cells by exploiting the phenomenon of molecular transfer from fibroblasts overexpressing these ligands. We analyzed the effects of the modified B-CLL cells on the number, phenotyp

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "OX40 ligand"

1

Ria, Massimiliano. "Role of the OX40 ligand/receptor pair in coronary artery disease /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-950-5/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Elhai, Muriel. "Thérapie ciblée anti-OX40 Ligand dans des modèles murins de Sclérodermie systémique." Thesis, Sorbonne Paris Cité, 2015. http://www.theses.fr/2015PA05T042/document.

Full text

Abstract:

La sclérodermie systémique (ScS) est une maladie auto-immune orpheline. Elle est caractérisée par une atteinte microvasculaire et une fibrose touchant la peau et les organes internes. La ScS est une maladie sévère avec une surmortalité significative. Jusqu’à présent, aucun essai thérapeutique n’a permis de démontrer qu’un produit ait une action anti-fibrosante et améliore significativement le pronostic de cette maladie. La physiopathologie de la ScS fait intervenir une combinaison de facteurs environnementaux et de facteurs de susceptibilité génétique. Récemment TNFSF4 a été identifié comme fa

APA, Harvard, Vancouver, ISO, and other styles

3

Kaneko, Hitomi. "Introduction of OX40 ligand into lymphoma cells elicits anti-lymphoma immunity in vivo." Kyoto University, 2005. http://hdl.handle.net/2433/144771.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Matsumura, Yumi. "Intracellular signaling of gp34, the OX40 ligand : Induction of c-jun and c-fos mRNA expression through gp34 upon binding of its receptor, OX40." Kyoto University, 2001. http://hdl.handle.net/2433/150501.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Yanagita, Soshi. "Retroviral transduction of acute myeloid leukaemia-derived dendritic cells with OX40 ligand augments their antigen presenting activity." Kyoto University, 2004. http://hdl.handle.net/2433/147543.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Gong, Ya-Zhuo. "Role of salivary gland epithelial cells in the differentiation and activation of T lymphocytes in primary Sjögren's syndrome." Thesis, Strasbourg, 2013. http://www.theses.fr/2013STRAJ100/document.

Full text

Abstract:

Le syndrome de Sjögren primitif (SJp) est une pathologie auto-immune caractérisée par une sécheresse occulobuccale, un infiltrat lymphocytaire des glandes salivaires, ainsi qu'une production d'auto-anticorps. Les cellules épithéliales salivaires (SGEC) des patients atteints de SSp expriment les molécules impliquées dans les réponses immunitaires et jouent le rôle des cellules présentatrices d’antigènes. Les lymphocytes T folliculaires (LTf) jouent un rôle important en activant les lymphocytes B via la sécrétion d’interleukine (IL)-21. Une augmentation de la proportion de LTf est observée dans

APA, Harvard, Vancouver, ISO, and other styles

7

Karpf, Léa. "Systematic Study of OX40 Ligand Context-Dependent Function on Human T Helper Cell Polarization A Quantitative Multivariate Model of Human Dendritic Cell-T Helper Cell Communication TH Cell Diversity and Response to Dupilumab in Patients With Atopic Dermatitis Inborn Errors of Type I IFN Immunity in Patients With Life-Threatening COVID-19 Quantitative Modeling of OX40 Ligand Context-Dependent Function on Human T Helper Cell SARS-CoV-2 Induces Activation and Diversification of Human Plasmacytoid Pre-Dendritic Cells." Thesis, université Paris-Saclay, 2020. http://www.theses.fr/2020UPASL044.

Full text

Abstract:

L'immunité adaptative est principalement orchestrée par des lymphocytes T CD4 auxiliaires. Ils ont la capacité de se polariser en plusieurs sous-populations, chacune associée à un phénotype approprié au pathogène rencontré. L'activation des lymphocytes T auxiliaires peut être régulée par des checkpoints immunitaires co-stimulateurs, tel que OX40 Ligand, ou co-inhibiteurs. Ces molécules ont été étudiées individuellement, dans des conditions spécifiques. Cependant, la contexte-dépendance pourrait expliquer une grande partie de la variabilité fonctionnelle des biomolécules. Il n'y a actuellement

APA, Harvard, Vancouver, ISO, and other styles

8

Fujita, Tomoko. "Type 1 interferons attenuate T cell activating functions of human mast cells by decreasing TNF-α production and OX40 ligand expression while increasing IL-10 production". Kyoto University, 2007. http://hdl.handle.net/2433/135668.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "OX40 ligand"

1

Kumar, Prabhakaran, Zarema H. Arbieva, Mark Maienschein-Cline, Balaji B. Ganesh, Suresh Ramasamy, and Bellur S. Prabhakar. "Induction of Antigen-Independent Proliferation of Regulatory T-Cells by TNF Superfamily Ligands OX40L and GITRL." In Methods in Molecular Biology. Springer US, 2020. http://dx.doi.org/10.1007/978-1-0716-1130-2_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ishii, Naoto, Takeshi Takahashi, Pejman Soroosh, and Kazuo Sugamura. "OX40–OX40 Ligand Interaction in T-Cell-Mediated Immunity and Immunopathology." In Advances in Immunology. Elsevier, 2010. http://dx.doi.org/10.1016/s0065-2776(10)05003-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "OX40 ligand"

1

Bleck, B., MR Ahsan, and J. Reibman. "Diesel Exhaust Particle (DEP)-Treated Human Airway Epithelial Cells Up-Regulate Dendritic Cell (DC) Expression of OX40 Ligand and Notch Ligand Jagged-1." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4286.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Palucka, AK, A. Pedroza, C. Aspord, M. Gallegos, E. Burton, and J. Banchereau. "Breast cancer instructs dendritic cells to express OX40 ligand and to prime pro-inflammatory type 2 CD4+ T cells that facilitate tumor development." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-1050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

McGlinchey, Kelly, Kathy Mulgrew, Chad Morris, et al. "Abstract 4275: Agonist OX40 ligand fusion proteins induce effector T cell proliferation, block regulatory T cell function and can combine with immune checkpoint inhibitors to promote antitumor immunity in preclinical models." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4275.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "OX40 ligand"

1

Weinberg, Andrew D. Production of a Novel OX40 Ligand for Clinical Use. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada614102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Weinberg, Andrew D. Production of a Novel OX40 Ligand for Clinical Use. Defense Technical Information Center, 2012. http://dx.doi.org/10.21236/ada583509.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Weinberg, Andrew D. Production of a Novel OX40 Ligand for Clinical Use. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada594395.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Weinberg, Andrew D. Production and Characterization of a Novel OX40 Ligand for Clinical Use. Defense Technical Information Center, 2010. http://dx.doi.org/10.21236/ada542444.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Weinberg, Andrew D. Production and Characterization of a Novel OX40 Ligand for Clinical Use. Defense Technical Information Center, 2012. http://dx.doi.org/10.21236/ada566405.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Weinberg, Andrew D. Production and Characterization of a Novel OX40 Ligand for Clinical Use. Defense Technical Information Center, 2011. http://dx.doi.org/10.21236/ada561369.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!